Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Unknown 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Recurrence 3Colorectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 12Rituximab 10Gemcitabine 9Paclitaxel 8Bendamustine Hydrochloride 8Lenalidomide 7Decitabine 7Cytarabine 7Carboplatin 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Bevacizumab 4Antilymphocyte Serum 4venetoclax 3pomalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Recurrence × Automobiles × Clear all
NCT04089215 2023-11-24

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2 Unknown
82 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05727683 2023-02-14

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 1 Unknown
33 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04943016 2021-06-29

CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies

National Taiwan University Hospital

Phase 1 Unknown
12 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡